TAC and the other plaintiffs ask that this program be created within three months. The program should include voluntary HIV/AIDS counseling and testing, the provision of nevirapine "where appropriate" and a supply of formula to help prevent HIV transmission through breast-feeding. This lawsuit has received support from over 150 health professionals, trade unions, religious organizations, and human rights groups.
Boehringer Ingelheim has offered to provide nevirapine free of charge to developing nations. Currently, South Africa only offers the drug through 18 pilot programs across the country. The government states that it is focusing on researching the issue, studying safety issues and effectiveness.
According to TAC, nearly 300,000 women with HIV will give birth in the next year. The majority do not know their HIV status and are not provided information or access to treatment that can reduce the risk of HIV transmission to their child. TAC predicts that at least 70,000 children could become infected with HIV during labor and breastfeeding.
TAC is asking for individuals and organizations around the world to send letters of support for their efforts. These letters will help with their court case and demonstrate that they are not alone in their fight. This is an easy, yet powerful, way to show solidarity for their efforts to reduce the spread of HIV in South Africa.
Thanks to Health GAP (Global Access Project) for the information contained in this Alert. You can learn more about Health GAP at www.globaltreatmentaccess.org. For more information about the Treatment Action Campaign, go to www.tac.org.za.
I am writing in support of Treatment Action Campaign's legal action to guarantee access to HIV preventive therapy for pregnant women and infants in South Africa as part of a comprehensive program for the prevention of mother-to-child transmission of HIV.
It has been demonstrated that access to antiretroviral drugs can dramatically reduce transmission of HIV from pregnant women to children. I strongly support TAC's efforts on this issue.